Fig. 6
From: A novel HVEM-Fc recombinant protein for lung cancer immunotherapy

HVEM-Fc altered the immune landscape in the TME. Notes: A Gzma+ NK cell abundance was more pronounced in the treatment group; B-E The proportion of Hp+ and Isg15+ cells significantly increased after HVEM-Fc treatment compared with the control group, While the ccl3+ and Rpl13+ decreased after treatment; F-G The apCAF subpopulations increased significantly while myCAF decreased after treatment; H-I Heatmap demonstrating the Pearson correlation between the cell-type abundance for various immune cell types; J-K The HVEM-Fc treatment group showed significant interactions between CTLs, NK cells and tumor cells in the number and strength of communications; L The alterations in signaling pathways after HVEM-Fc treatment; M–O The comparison of the subsets of immune cells in the peripheral blood and lung tumors of treatment group